Latest PuraMed BioScience Inc. Stories
SCHOFIELD, Wis., May 21, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the results of clinical trials that found its over-the-counter migraine medication product, LipiGesic(®) M, has "robust efficacy". With recent statistics showing nearly 39 million Americans suffering from migraine headaches, studies show that LipiGesic M provides a safe, highly effective...
SCHOFIELD, Wis., May 15, 2013 /PRNewswire/ -- PuraMed BioScience(®), Inc., (OTCBB: PMBS) announces the launch of its Business-to-Business Migraine First Aid Kit((TM)). The program, which is available to businesses of any size, can help migraine sufferers stay on the job and stay productive by eliminating migraine pain and associated symptoms. "Knowing that migraines are debilitating for many people we looked at their impact on the business sector," said Charles Phillips, board...
SCHOFIELD, Wis., May 13, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces the receipt of its first International order for LipiGesic® M its non-drowsy, clinically tested, over-the-counter migraine relief product. Through an agreement with Biokemical, PuraMed BioScience has now expanded international distribution of LipiGesic M to Columbia, South America....
SCHOFIELD, Wis., April 24, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research had issued a research opinion on the company and its flagship product, LipiGesic® M. Report Highlights - Non-Prescription Product to Treat Migraine Headaches- Product Shown to Outperform #1 Prescription Competitor- Holds Patent on Product- Product Currently...
SCHOFIELD, Wis., April 18, 2013 /PRNewswire/ -- PuraMed BioScience(®), Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces its production vendors for the mass manufacturing and packaging of LipiGesic(®) M (www.lipigesic.com/about) its clinically tested, non-drowsy, migraine relief product. "Through our current relationships with our third-party vendors, PuraMed has the established and proven...
SCHOFIELD, Wis., April 12, 2013 /PRNewswire/ -- Healthcare product developer PuraMed BioScience®, Inc. (PMBS: OTCBB) announced plans this week to expand the retail sales efforts of its OTC migraine product LipiGesic® M to an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target, food store chains such as SuperValu, Kroger and Safeway, and additional well-known regional drugstores. PuraMed has selected its targeted retailers according to...
SCHOFIELD, Wis., March 5, 2013 /PRNewswire/ -- PuraMed BioScience(®), Inc., (PMBS: OTCBB) announces that the reanalysis of the clinical trial results of its homeopathic formulation, LipiGesic(®) M, found that the migraine medication has "robust efficacy." These results were featured in the February 2013 issue of Headache: The Journal of Head and Face Pain, the official journal of the American Headache Society(®). The article, Sublingual Feverfew/Ginger (LipiGesic M) Reanalysis of...
SCHOFIELD, Wis., Feb. 26, 2013 /PRNewswire/ -- PuraMed BioScience(®), Inc., (OTCBB: PMBS), a publically traded company engaging in the research, development, and marketing of non-prescription medicinal and healthcare products, has engaged FOCUS LLC, an investment banking firm headquartered in Washington, DC, to explore strategic options for its patented migraine relief product, LipiGesic(®) M. FOCUS LLC provides a wide range of finance services to meet the needs of emerging...
SCHOFIELD, Wis., Jan. 15, 2013 /PRNewswire/ -- PuraMed BioScience(®), Inc, (OTCBB: PMBS) announces that its over-the-counter, homeopathic migraine pain reliever formulation, LipiGesic(® )M, has received a Notice of Allowance for its patent application from the United States Patent and Trademark Office. LipiGesic M's exclusive formulation of feverfew and ginger delivered in a sublingual (under-the-tongue), non-aqueous gel has been clinically studied for the treatment of acute...
SCHOFIELD, Wis., Nov. 13, 2012 /PRNewswire/ -- PuraMed BioScience(®), Inc,. (OTCQB: PMBS) announces that its homeopathic migraine formulation, LipiGesic(® )M, has been recognized as an excellent first-line therapy in the treatment of acute migraine. The declaration was made in the online article "Advances in Drug Development for Acute Migraine," [page 14] scheduled for publication in an upcoming printed issue of Drugs, a medical journal evaluating drugs and drug therapies read by...
